A randomized controlled trial of quetiapine for psychosis in Parkinson's disease.
about
Quetiapine in the treatment of psychosis in Parkinson's diseaseThe Efficacy and Safety of Antipsychotic Medications in the Treatment of Psychosis in Patients with Parkinson's DiseaseEvidence for the use of pimavanserin in the treatment of Parkinson's disease psychosisParkinson Disease and Dementia.Psychosis in Parkinson's Disease: Epidemiology, Pathophysiology, and Management.Treatment of psychosis and dementia in Parkinson's disease.Antipsychotics for the management of psychosis in Parkinson's disease: systematic review and meta-analysis.The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's diseaseAtypical antipsychotic therapy in Parkinson's disease psychosis: A retrospective studyParkinson's disease: the quintessential neuropsychiatric disorderPatterns and trends in antipsychotic prescribing for Parkinson disease psychosisPimavanserin for the treatment of Parkinson's disease psychosis.Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.An update expert opinion on management and research strategies in Parkinson's disease psychosisCognitive impairment and dementia in Parkinson's disease: clinical features, diagnosis, and management.Clinical review and treatment of select adverse effects of dopamine receptor agonists in Parkinson's disease.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of Alzheimer's disease and other dementias.Atypical antipsychotic drugs in the treatment of Parkinson's disease.Treating psychosis in movement disorder patients: a review.Novel pharmaceuticals in the treatment of psychosis in Parkinson's disease.The psychosis spectrum in Parkinson disease.Neuropsychiatric Issues in Parkinson's Disease.Quetiapine for Psychosis in Parkinson Disease and Neurodegenerative Parkinsonian Disorders: A Systematic Review.Evidence-Based Review of Pharmacotherapy Used for Parkinson's Disease Psychosis.Parkinson's disease psychosis: therapy tips and the importance of communication between neurologists and psychiatrists.Recognition and treatment of neuropsychiatric disturbances in Parkinson's disease.A fixed-dose randomized controlled trial of olanzapine for psychosis in Parkinson disease.Management of Psychosis in Parkinson's Disease: Emphasizing Clinical Subtypes and Pathophysiological Mechanisms of the Condition.Pimavanserin, a novel antipsychotic for management of Parkinson's disease psychosis.Management of neuropsychiatric symptoms in long-term care residents with Parkinson's disease: a retrospective cohort study.Predictors of response to a cognitive behavioral intervention for impulse control behaviors in Parkinson's disease.Parkinson's disease psychosis: presentation, diagnosis and management.Pimavanserin: A Novel Drug Approved to Treat Parkinson's Disease Psychosis.
P2860
Q24628941-8896DD80-F995-4A99-B4E3-E536DF1F0050Q26738456-4A31E817-1476-4B6B-AB91-AC659D29ECAFQ28074468-4B103F2B-E90B-47B8-B4E5-A4DA2C803222Q30248574-1DD1DAC4-9106-4DD3-AA34-B9327B5C9FC5Q30249553-6360E65B-2A23-4FD2-AD42-FC778981D21EQ30358337-8D3E471B-C508-4725-89CB-1A14E92C960DQ30489967-1576BB0E-01E2-4E5B-BFC9-20EBE4BAF0C1Q33607256-40390860-1CD7-4A22-B207-D49489269D47Q33810051-59F6AC9E-2BF5-4EAA-B80C-C20F467FDC24Q33917094-6C995924-0C85-4254-B559-13F5C2E6B8F9Q33957582-4850232D-75F6-4D87-93F2-9A64A4FF964AQ34369646-4F7DA56C-17F5-4629-A372-F2C288AB4564Q34660675-D694E486-7CE4-4B13-8730-FF8CC1A2CBDFQ35154278-CA0830F3-C590-47AD-8277-BBC261BA96ADQ35988441-6FEDD18D-FA8C-4CD0-A810-23C2878DB8F9Q37722750-D5C5A828-DD18-4F85-AC8F-C3C411D67D36Q37834619-85015B52-61AA-456A-9CA8-B2261C66BF01Q37957772-AD4219BB-939A-49F0-8241-12A2AFCD4BB8Q38213306-1F3FC962-73D5-4E7A-AA32-8DC40BDC34D3Q38258699-4021FAD3-DA6B-4287-9A4A-D5F13647B8F7Q38768169-0866AF8C-CCB1-4782-B3DE-966947AD05B4Q38799051-1941A82D-285F-4040-B880-92AA8D6AD74CQ38801245-DA0C5920-D1E1-4195-8710-4349B5541882Q38849634-759C54D7-83A9-487E-8F93-DCD06D38FB71Q38894971-E091B58E-AA13-4673-878E-965421C5DD88Q40626246-259CED80-BAA6-4FE4-AF4E-523DA4941F7EQ41812925-620AC7C4-551F-4E6E-ACEB-A4E6C891ABD6Q43375910-0BA6AB94-FABA-49EB-87B3-7E1B3FA6DAD7Q47794742-CC7FC21F-9855-4D4F-BA1D-A3205E0F877FQ50893332-FEAB72E9-BE00-45A1-B7E0-6EBBD1EB2E41Q50982859-96173DA0-9E55-4A5C-81CB-DFB6253E4985Q51781286-F83D19D8-5285-4328-AC31-CB62A92FC3EDQ52677977-F3BDC718-F0D7-40E2-B1C7-B0B836F3971D
P2860
A randomized controlled trial of quetiapine for psychosis in Parkinson's disease.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
A randomized controlled trial of quetiapine for psychosis in Parkinson's disease.
@en
type
label
A randomized controlled trial of quetiapine for psychosis in Parkinson's disease.
@en
prefLabel
A randomized controlled trial of quetiapine for psychosis in Parkinson's disease.
@en
P2860
P356
P1476
A randomized controlled trial of quetiapine for psychosis in Parkinson's disease
@en
P2093
Anthony S David
Michael Samuel
P2860
P304
P356
10.2147/NDT.S5335
P407
P577
2009-06-10T00:00:00Z